First Time Loading...
G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 830.05 INR 1.07% Market Closed
Updated: May 16, 2024

Glenmark Life Sciences Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Glenmark Life Sciences Ltd
Cost of Revenue Peer Comparison

Comparables:
DRREDDY
CIPLA
SUNPHARMA
ZYDUSLIFE
T
TORNTPHARM

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Life Sciences Ltd
NSE:GLS
Cost of Revenue
-₹10B
CAGR 3-Years
-3%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cost of Revenue
-₹82.1B
CAGR 3-Years
-8%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cost of Revenue
-₹88.2B
CAGR 3-Years
-2%
CAGR 5-Years
-6%
CAGR 10-Years
-9%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cost of Revenue
-₹105.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-15%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Cost of Revenue
-₹63.1B
CAGR 3-Years
-9%
CAGR 5-Years
-7%
CAGR 10-Years
-9%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cost of Revenue
-₹27.1B
CAGR 3-Years
-8%
CAGR 5-Years
-5%
CAGR 10-Years
-9%

See Also

What is Glenmark Life Sciences Ltd's Cost of Revenue?
Cost of Revenue
-10B INR

Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Cost of Revenue amounts to -10B INR.

What is Glenmark Life Sciences Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-23%

Over the last year, the Cost of Revenue growth was 1%. The average annual Cost of Revenue growth rates for Glenmark Life Sciences Ltd have been -3% over the past three years , -23% over the past five years .